Mark H Rozenbaum, Liping Huang, Johnna Perdrizet, Alejandro Cane, Adriano Arguedas, Kyla Hayford, Maria J Tort, Ruth Chapman, Desmond Dillon-Murphy, Vincenza Snow, Erica Chilson, Raymond A Farkouh
BACKGROUND: As of June 2023, two pneumococcal conjugate vaccines, 20- (PCV20) and 15- (PCV15) valent formulations, are recommended for US infants under a 3 + 1 schedule. This study evaluated the health and economic impact of vaccinating US infants with a new expanded valency PCV20 formulation. METHODS: A population-based, multi cohort, decision-analytic Markov model was developed to estimate the public health impact and cost-effectiveness of PCV20 from both societal and healthcare system perspectives over 10 years...
January 7, 2024: Vaccine